Growing concern that most published results, including those widely agreed upon, may be false are rarely examined against rapidly expanding research production. Replications have only occurred on small scales due to prohibitive expense and limited professional incentive. We introduce a novel, high-throughput replication strategy aligning 51,292 published claims about drug-gene interactions with high-throughput experiments performed through the NIH LINCS L1000 program. We show (1) that unique claims replicate 19% more frequently than at random, while those widely agreed upon replicate 45% more frequently, manifesting collective correction mechanisms in science; but (2) centralized scientific communities perpetuate claims that are less likely to replicate even if widely agreed upon, demonstrating how centralized, overlapping collaborations weaken collective understanding. Decentralized research communities involve more independent teams and use more diverse methodologies, generating the most robust, replicable results. Our findings highlight the importance of science policies that foster decentralized collaboration to promote robust scientific advance.
Introduction
Concern over reliability (1) and reproducibility (2, 3) in science calls into question the cumulative process of building on prior results published by others. In a publication environment that rewards novel findings over verifications (4, 5) , scientists remain uncertain about the published claims they assemble into new research designs and discoveries. In this paper, we demonstrate a claim replication strategy that repurposes high-throughput experiments to evaluate the replication likelihood for tens of thousands of scientific claims curated from a wide range of research articles.
Our strategy builds on the synergy of two advances. First, databases of empirical claims on many topics, ranging from material science to biomedicine (6, 7) , are extracted from literature and linked to digital archives of scientific articles such as MEDLINE and Web of Science, making possible systematic analysis of features that characterize the provenance of a scientific claim, such as where, when, who, and how many experiments provided findings for and against it (8) . Second, high-throughput experiments driven by consistent, programmable robots have become increasingly widespread, initially in genome sequencing (9) but extending to many domains, including drug-gene interactions.
These experiments provide large-scale biomedical data enabling simultaneous estimation of the replication likelihood for many prior published claims.
Replication failures are typically attributed to systemic bias in a publication system that favors positive results (1). This incentivizes questionable research choices such as p-hacking (10, 11) , "flexible" data analysis (12) , low statistical power (13) , selective reporting ("the file drawer problem") (14) , and confirmation bias (15) , which generate false results unlikely to replicate in future experiments (12) .
Here we investigate the social and methodological structure of scientific and methodological communities that coalesce around scientific claims. What network dependencies linking scientists and their experimental methods produce the most robust, replicable claims? We hypothesize that an empirical claim tested by a decentralized community of non-overlapping teams with diverse training and prior knowledge, using distinct methods under varying experimental conditions will produce robust knowledge, likely to replicate in future experiments. By contrast, increased collaboration (16) , growing teams (17) , star scientists (18, 19) , and expensive, shared equipment trace a experiments, we selected interaction effects in which a drug "increases expression" or "decreases expression" of an mRNA in humans (effect magnitudes were not recorded).
The database identifies source articles in which the finding is claimed (i.e., PubMed ID), which enabled examination of article content (e.g., methods) and metadata features (e.g., authors).
To estimate replication likelihood, we map our corpus of drug-gene claims to high-throughput experimental data from the NIH LINCS L1000 program. The program generated 1.3M gene expression profiles from 42,080 chemical and genetic perturbagens across cell lines, time points, and doses (32) . We used profiles induced by chemical perturbagens, amounting to 19,811 small molecule compounds (including FDA approved drugs). To measure relative gene expression resulting from chemical perturbations, the LINCS L1000 team computed robust z-scores that represent differential expression signatures. We combined the z-scores across signatures using a bootstrapped modification of Stouffer's method (33, 34) to generate drug-gene interaction triples of (i) drug, (ii) gene (mRNA), and (iii) combined z-score indicating experimental effect size and effect direction. We matched drug-gene interaction triples from the LINCS L1000 experiments to triples in CTD, and found 51,292 drug-gene interaction claims at the intersection, corresponding to 60,159 supportive and 4,253 opposing findings from the literature, annotated from 3,363 scientific papers.
We distinguish between robustness to social, methodological and intellectual dependencies and robustness to experimental conditions (27) like time, dosages, cells, or tissues, which delimit the potential for a drug-gene interaction to generalize. In all subsequent models, we control for the variability of drug-gene interactions in LINCS L1000 to disentangle features of experimental and biological heterogeneity from global patterns of (in)dependence.
Our high-throughput replication strategy evaluates reliability of the overall scientific claim rather than of any particular finding. The latter would require precise reproduction of the original research following the original experimental protocol (35) .
Nevertheless, collective agreement across many articles may serve as evidence of a generalized claim robust to any one technique (28, 36) , scientist, research group, or biological setting (e.g., cell line), thereby justifying increased confidence in the claim's widespread scientific and biomedical relevance.
Results
We observe a long-tailed distribution of published findings in support of a given scientific claim (Fig. 1A) . Most claims are supported by findings in one (89%) or two (8%) articles, while few appear in many articles. The distribution of experimental effect sizes over drug-gene interactions in LINCS L1000 decays much more slowly (Fig. 1D) .
Published findings widely agree on the direction of drug-gene interactions (93%) (Fig. 1A) . In contrast, the majority of interaction effect-sizes (59%) in LINCS L1000 across experimental conditions are statistically undetermined (Fig. 1D) . We find that consensus in the literature is positively associated with social dependencies. A pair of findings about a drug-gene interaction reported in papers with shared author(s) are significantly more likely to agree in the direction of the effect (0.989; 95% CI: 0.984, 0.993; 2,514 pairs of papers) than findings reported in socially independent papers (0.889; 95% CI: 0.884, 0.893; 20,846 pairs of papers) (Fig. S2 ).
We also find that generalizable interactions, which converge across experimental conditions in LINCS L1000, are more likely to replicate published claims (RR = 0.60) than interactions that vary across conditions (RR = 0.52), which are indistinguishable from random (RR = 0.501) in our corpus (Fig. 1E) . We define the replication success (R = 1; 0 otherwise) of a claim as the effect size (combined z-score) in LINCS L1000 matching the direction (increase or decrease) of the effect claimed in literature (see SM). For each claim, we summarize the probability of support (dashed line) using the lower bound on the 95% posterior credible intervals (PCI). (C) Typology of drug-gene claims from the literature on the basis of claim's distribution of support compared to the null value of 0.5. Number of claims included in a category provided in brackets. (D) Effect sizes (combined z-scores) for drug-gene interactions derived from LINCS L1000 experiments. On top, the distribution of druggene interactions against absolute experimental effect size in LINCS L1000 (log-log scale). On bottom, the proportion of significant and insignificant interactions in LINCS L1000. We established significance at the 0.05 level by bootstrapping (10,000 iterations) the combined z-score for each of the 51 A ll s ig n if ic a n t A central concern is whether the replication problem applies only to novel and rare claims or if it also afflicts widely supported results, as recently hypothesised (37, 38) . To integrate collective support in the literature over multiple claim sources, we design a binomial Bayesian model with a uniform prior that accommodates skewed distributions (39) like that of findings per claim we observed. To estimate the probability of support for each drug-gene claim, we assume that the number of supportive published findings in findings about that claim is drawn from a binomial distribution,
. The model allocates higher probability to scientific claims unanimously supported in a large number of articles and lower probability to infrequent and disputed claims (Fig. 1B) .
We find a strong relationship between scientific support in the literature !"#$ and the probability of replication success, ranging from 0.507 (95% CI: 0. 492, 0.522) for claims with the least support to 0.705 (95% CI: 0.665, 0.743) for claims with the largest, controlling for biological and experimental variability in LINCS L1000 (Fig. S3A ).
When we consider only significant drug-gene interactions (Fig. S3B) , which generalize across experimental conditions, the probability of replication for top-supported claims reaches 0.798 (95% CI: 0. 751, 0.845).
To examine the hypothesis that convergent drug-gene claims more likely replicate than those claimed rarely or disputed in literature, we categorized claims on the basis of their distribution of support (Figs. 1C and S4; see SM). We found that claims with "Very high" (RRI = 45.4%; SEM ± 13.5%) and "High" (RRI = 34.5%; SEM ± 7.6%) support in the biomedical literature are significantly more likely to replicate in high-throughput experiments than claims with "Low" (RRI = 19%; SEM ± 1.1%) and "Moderate" (RRI = 16.2%; SEM = 3.3%) support (Fig. 1F) . The replication of "Low" and "Moderate" support claims is consistent with estimates (~11-25%) from recent biomedical reproducibility studies (2, 3) , but those receiving support from multiple sources is much higher. "Contradictory" claims are significantly less likely to replicate than random. They are also associated with greater experimental variability ( We examine the impact of network dependencies on claim replicability by fitting logistic regression models that predict replication success against the measures described above and defined for each claim, using a sub-corpus of 2,493 claims with determined direction of the drug-gene effect in the literature ( !"#$ = 68% PCI > µ < 68% PCI) and in LINCS L1000. Figure 
for logistic models of independent predictors with 95% error bounds.
An alternative explanation of replication success is the biological tendency for some drug-gene interactions to generalize across conditions and so replicate in future experiments. Figure 2F shows that experimental variability has a small, insignificant negative effect, and that support from multiple, decentralized teams are much more informative predictors of replication success.
Our combined model also controls for journal prominence J, which we measure with journal eigenfactor (40), a score that credits journals receiving many citations from highly cited journals. Claim replication increases with journal prominence (Figs. 2F and 2L), but prominent journals are responsible for only a tiny fraction of all claims, which warrants our evaluation strategy and the practice of extracting and archiving findings from a wide range of journals (6) . 
Measuring variability in LINCS L1000
To measure how each drug-gene interaction varies across cell lines, dosages, and durations in LINCS L1000, we computed the coefficient of variation. The coefficient of variation (CI) is the ratio of the standard deviation to the absolute value of the mean:
. In comparison to scale-dependent measures of variability, CI is a normalized measure that allows us to make comparisons across drug-gene interactions.
Modelling claims' support in literature We apply a binomial Bayesian model (39, 41, 42) to estimate the probability of scientific support for each drug-gene claim given the number of supportive findings in all findings N reported in CTD about a particular drug-gene interaction. We assume that the prior distribution of is uniform on the interval [0,1]: θ !~U niform(min = 0, max = 1). This uninformative prior considers all possible probability support values as equally possible and is suitable for the skewed distribution of findings over drug-gene claims. We assume that the number of findings in support of a drug-gene claim follows a binomial
Then, the posterior density for is
We approximated the posterior density of for each drug-gene claim by performing 10,000 Markov chain Monte Carlo (MCMC) sampling iterations (2,500 burn in iterations) for each drug-gene claim using the Metropolis-Hastings MCMC sampler implemented in the PyMC package (version 2.3.6) for Python. To improve convergence, we approximate the maximum posterior (MAP) before running the MCMC sampler (39) .
Typology of drug-gene claims
To avoid setting arbitrary thresholds to categorize claims by their support in literature, we used the posterior distributions from our Bayesian model of support. For each claim, we estimated the overlap between the posterior credible intervals (PCI) and the null value of µ = 0.5 ( Fig. 1C) : Very high support claims ( !"#$ 95% PCI exceeds µ) yield agreement from multiple papers (~7 papers on average), amounting to 325 claims that are supported by 2,241 findings, but only opposed by 21; High support claims (80% PCI ≥ !"#$ < 95% PCI exceeds µ) yield agreement from 3 papers on average (N = 1,083 claims, supported and opposed in 3,525 and 42 articles, respectively); Moderate support claims (68% PCI ≥ !"#$ < 80% PCI exceeds µ) yield agreement from 2 papers on average (N = 3,743 claims, supported and opposed in 7,557 and 38 articles, respectively); Low support claims (68% PCI ≥ !"#$ < 80% PCI contains µ) are overwhelmingly supported by a single paper or opposed by virtually the same number of papers that support them such that the direction of the effect is undetermined (N = 46,064 claims, supported and opposed in 46,735 and 3,668 articles, respectively). Contradictory claims ( !"#$ 68% PCI is smaller than µ) generate lower support than expected as a greater number of papers reported findings in the opposite direction (N = 77 claims, supported and opposed in 101 and 484 articles, respectively) (Fig. S4) .
Null model for estimating relative replication increase
We define replication as a binary variable ∈ {0,1}, where R = 1 indicates that the direction (increase or decrease) of the effect claimed in literature is matched by the combined z-score in LINCS L1000, and R = 0 otherwise. To estimate the amount of relative replication increase (RRI), we first empirically established the expected or random replication rate !"#$ by iteratively randomizing LINCS L1000 drug-gene interactions. For each randomization, we computed the replication rate for all significant drug-gene claims (N = 21,181) as well as for the collection of very high support (N = 136), high support (N = 406), moderate (N = 1,908), low (N = 18,688), and contradictory (N = 43) claims against the drug-gene interactions from LINCS L1000 that randomly matched them. We repeated the estimation procedure 100,000 times to generate randomized distributions, mean randomized replication rates RR rand , and standard errors of the RR rand (or SEM) for each claim type. This randomization model takes into account biases in the distribution of published claims, as when disproportionately more claims of a certain direction, either "increasing" or "decreasing", are present. This allows us to conservatively estimate the expected replication rate on the basis of empirical data, rather than assuming a random null value of 0.5. We bootstrapped (100,000 iterations with replacement) the observed replication vector for each type of claim to generate distributions of observed replication rates, mean observed replication rates RR obs , and the standard error of RR obs (or SEM). We used the randomized and bootstrapped distributions for each type of claim to estimate the percentage relative replication increase:
Claim multilayer networks To investigate the robustness of drug-gene claims, we represent each claim as a multilayer network = ! , ! , (30) . The network consists of four layers, which we plot using the Multilayer Networks Library for Python (Pymnet) (43) . Nodes ! in the network are scientific papers. In each layer L, edges between pairs of papers represent either a binary relationship of agreement and disagreement about effect direction ( ! ), or the amount of overlap between the two articles' authors ( ! ), methods ( ! ), and references ( ! ). For this analysis, we exclude claims with low support as estimated via our Bayesian model because they are primarily reported by a single paper and therefore, lack independence and robustness. To examine the impact of claim robustness on the probability of replication in high-throughput experiments, we interrogated only interactions that produce a replication signal by posting a statistically significant effect size. These are claims that generalize across experimental and biological conditions in LINCS L1000. By exploring only statements having significant agreement within the literature and within LINCS L1000, we can directly examine the effect of social, methodological, and epistemic dependencies on shaping agreement between literature and high-throughput experiment. The sub-corpus of claims both supported in the literature and significant within LINCS L1000 consists of 2,493 claims, associated with 6,272 supporting and 339 opposing findings from 1,282 papers. For each claim, we create a multilayer co-paper network and model the predictive power of each layer on the replicability of a claim in the LINCS L1000 experiments.
Quantifying overlap between articles' authors, methods, and references To quantify the amount of overlap between papers, we used the Jaccard coefficient (JC). For any two sets of paper's attributes-i.e., authors, methods, or references-! and ! , JC is the size of intersection divided by the size of the union:
. The resulting quantity represents the edge weight between a pair of articles in the respective network layers of shared authors ( ! ), methods ( ! ), and references ( ! ). Each drug-gene claim constitutes an undirected, multilayer network of papers connected via such weighted edges across layers (see Fig  2A) .
Independence of findings
We define an independence score IND as the proportion of maximum possible edges (44) in a network layer
, where is the sum over all weighted edges in a claim's respective layer of shared authors, methods, or references. The independence scores for social, methodological, and prior knowledge approaches 1 when most papers with findings in support of a claim share no common authors, methods, and references, and 0 when all papers share all of their authors, methods, and references, respectively.
Social independence
We used the MEDLINE/PubMed database to extract the set of authors for each paper. To measure the overlap between two sets of authors, we need individual identifiers for authors. Authors' name disambiguation is a common problem in research on scientific knowledge production. We used the individual identifiers based on author last name and initials. We note that because we assessed authors separately for each claim, our conservative matching procedure is very unlikely to produce false positive author linkages, and so our author co-paper network should be considered a lower bound for author co-paper density. For the sub-corpus of 2,493 claims, sourced from 1,282 papers, we estimated a mean of 6.4 authors per paper and a mean of 23.5 authors per scientific community defined here as the total number of authors that have published papers reporting a drug-gene claim. For the set of papers supporting a claim, we applied JC to measure the overlap between any two sets of papers' authors and utilized the output to compute claim's social independence !"# using our independence score.
Methodological independence
We compiled a controlled vocabulary of 3,074 terms (incl. synonyms) concerning methods, techniques, and experimental apparatus used in biomedical research using ontologies of biomedical investigations (45) and statistics (46) . We then used the RESTful API Web Service of Europe PMC to query the methods sections from 4.4 million full text articles and extracted, on aggregate, 13,095 terms for 488 articles (38%).
In parallel, for all 1,282 articles that share a drug-gene claim, we applied fuzzy matching against our vocabulary using the difflib module in Python and extracted 12,135 terms from abstracts available in MEDLINE/PubMed. We combined the outputs from the two search procedures. Then, for the set of papers supporting a claim, we again used JC to measure the overlap between any two sets of papers' methods and then employed our independence score to measure claim's methodological independence !"# .
Prior knowledge independence To examine whether a pair of publications is exposed to similar or dissimilar prior information, we use the notion of bibliographic coupling (47), i.e., the number of citations any two papers share. To compute bibliographic coupling, we used the Web of Science citation data. Out of 1,282 papers sharing a drug-gene claim with at least one other paper, we mapped 1,234 PubMed IDs to Web of Science IDs and performed bibliographic coupling on this subset using Python modules Tethne (48) and NetworkX (49) . 880 of our 1,234 papers were coupled bibliographically by at least one paper. Consistent with the procedure we applied to measure shared authors and methods, we used JC to measure the overlap between any two sets of papers' citations and then employed our independence score to measure claim's prior knowledge independence !"# .
Centralization of scientific communities
To quantify the centralization of scientific communities in the bipartite author-article networks for each claim, we employed the Gini coefficient. The Gini coefficient is used to measure the heterogeneity of distributions in social and information networks (50) . The coefficient ranges between 0 and 1. In the context of a bipartite author-article network, the coefficient approaches 0 when all investigators author equal numbers of articles about a claim and increases to 0.3 and above (depending on the number of articles), when one investigator authors all articles and all others author only one. The Gini coefficient can be also represented as a percentage ranging from 0 to 100, as in Figure 2D -E. While other measures of network centralization are available (e.g., Freeman's centralization (51)), the Gini coefficient, and the Lorenz curve on which it is based, is independent from the underlying degree distribution, making it suitable for comparisons among networks with different size and mean degree (50, 52) .
Journal prominence
To measure journal prominence, we employed the journal eigenfactor score (40) . The eigenfactor score acts like a recursively weighted degree index by rating journals highly that receive citations from journals that are themselves highly cited. Using the Web of Science database, we computed journal eigenfactor scores for 3,162 papers (94% of all 3,363 papers in our corpus) published in 656 journals between 1995 and 2016. For the sub-corpus of 1,282 papers with shared drug-gene claims, we recovered 1,212 papers or 95% published in 496 journals. For each claim, we computed mean journal eigenfactor scores by averaging over the eigenfactor score of all journals that published a paper reporting findings in support of the claim. The distribution of mean journal eigenfactor scores (i.e., journal prominence) per claim is highly skewed (Figs. S4 and S5 ), indicating that claims receive overwhelmingly support from findings published in low and medium ranked journals. This highlights the value of archiving findings across a wide range of journals, as do CTD and other scientific database projects, which makes possible our large-scale evaluation of scientific output.
Shared authors and scientific agreement
To examine whether papers with shared authors are more likely to agree on the direction ("increasing expression" or "decreasing expression") of the drug-gene interaction, we identified all pairs of papers with shared or distinct authors that reported findings about the same drug-gene pair irrespective of the directionality of the effect. We found that among the 2,514 edges between papers with shared authors, 2,486 (98.9%) agreed on the direction of the effect. By comparison, among the 20,846 pairs of papers with distinct authors, 18,527 (88.9%) agreed on the direction of the effect. To examine the differences in agreement rates among papers with common versus distinct authors, we performed a two-tailed bootstrap test (100,000 samples) (Fig. S2 ).
Predictors of replication success
We estimate logistic regression models to predict claim replication R [Replicated = 1, Non-replicated = 0] as a function of support in the literature !"#$ , social independence !"# , methodological independence !"# , prior knowledge independence !"# , centralization , journal prominence , and experimental variability . First, for exploratory purposes, we model each variable independently (see Table S1 ):
Second, we model our variables simultaneously (see Table S2 ):
Third, we estimate two interaction models to examine the effect of support in the literature on replication success as a function of social independence and centralization, respectively (see Figs. 3 and S8-9):
To estimate and visualized the logistic regression models, we used the "glm" function and the "effects" (53) and "sjPlot" (54) packages for R.
Data Analysis
Robustness analysis Some of our variables are correlated (e.g., methodological independence and prior knowledge independence; see Fig. S7 ), which is to be expected as they capture related dimensions of scientific knowledge production. We performed a multicollinearity test using the variance inflation factor (VIF). The variance inflation factors vary from low for variability in LINCS L1000 (VIF = 1.015), journal prominence (VIF = 1.135), and support in literature (VIF = 1.534) to moderate for centralization (VIF = 3.162), methodological independence (VIF = 3.752), prior knowledge independence (VIF = 4.681), and social independence (VIF = 4.900). We observe no predictor with high variance inflation factor, i.e., VIF ≥ 10. We removed the two variables with the highest VIF > 4 and refit our logistic regression model. In the refitted model, both support in the literature and decentralization of scientific communities remain strong and significant predictors of replication success (Fig. S10) . Further, we verified that the effects of support from the literature and community centralization on claim replication success are not dominated by outliers. Recall the long-tailed distribution of findings per claim, with few claims receiving support from many published findings (Fig. 1A) . We removed claims supported by 10 or more findings, amounting to 26 claims supported by 426 findings and found that support from the literature (OR 34.785; 95% CI: 12.518, 96.662, P = 1.00e-11) and community centralization (OR 0.335; 95% CI: 0.249, 0.451, P = 5.57e-13) remain strong and significant predictors of replication success, after controlling for biological and experimental variability in LINCS L1000 (OR 0.726; 95% CI: 0.429, 1.232; P = 0.236). Similarly, the distribution of findings per paper and per pair of papers is heterogeneous (Fig. S11) . We removed the largest set of 796 drug-gene claims reported by a pair of papers and still found that the effect of support from the literature (OR 19.512; 95% CI: 7.193, 52.929, P = 5.37e-09) and centralization (OR 0.432; 95% CI: 0.287, 0.65, P = 5.71e-05) holds and is not explained by variability in LINCS L1000 (OR 0.574; 95% CI: 0.279, 1.181; P = 0.131). for comparability. N = 2,493 claims. *** P < 0.001; ** P < 0.01; * P < 0.05. for comparability. N = 2,493 claims. *** P < 0.001; ** P < 0.01; * P < 0.05. for comparability. N = 2,491 claims. *** P < 0.001; ** P < 0.01; * P < 0.05. for comparability. N = 2,493 claims (N = 2,491 in the Journal eigenfactor model); *** P < 0.001; ** P < 0.01; * P < 0.05.
Variability in LINCS L1000

